Download Free Medical Endometrial Cancer and Lynch Syndrome PowerPoint Presentation

Endometrial Cancer and Lynch Syndrome PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Endometrial Cancer & Lynch Syndrome” by Dario R. Roque, MD.

This medical PowerPoint presentation is about endometrial Cancer and Lynch Syndrome.

Endometrial cancer is a type of cancer that develops in the lining of the uterus, known as the endometrium. It is the most common gynecologic cancer in women in the United States. Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is an inherited condition that increases the risk of developing certain types of cancer, including endometrial cancer.

Lynch syndrome is caused by mutations in genes that help repair DNA damage in cells. Individuals with Lynch syndrome have an increased risk of developing colon, endometrial, ovarian, stomach, pancreatic, and other types of cancer. In fact, women with Lynch syndrome have a 40-60% lifetime risk of developing endometrial cancer, which is much higher than the general population.

Because of the increased risk of endometrial cancer in individuals with Lynch syndrome, regular screening is recommended. This may include transvaginal ultrasounds, endometrial biopsies, and/or other imaging tests. If endometrial cancer is detected, it is typically treated with surgery to remove the uterus and surrounding tissue, followed by additional therapies such as radiation and/or chemotherapy.

Individuals with Lynch syndrome may also consider risk-reducing surgery, such as removal of the uterus and ovaries, to reduce the risk of developing endometrial and ovarian cancer. Additionally, regular colonoscopies are recommended to screen for colon cancer, as well as screening for other types of cancer based on individual risk factors.

It is important for individuals with Lynch syndrome to work with a healthcare professional who specializes in genetics and cancer to develop an individualized screening and management plan based on their specific risk factors.

Tags : Endometrial Cancer, Lynch Syndrome, Gynecologic Oncology, Gynecologic Oncology PowerPoint presentation

Published on : May 29, 2023 | Views : 1197 | Downloads : 9

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Dario R. Roque, MD Endometrial Cancer & Lynch Syndrome
Slide 2-

Endometrial Cancer 2020 Estimated New Cases
Slide 3-

Early Detection Makes a Difference
Slide 4-

Endometrial Cancer Risk Factors Chronically increased estrogen levels Unopposed estrogen therapy Tamoxifen Anovulation Obesity Estrogen secreting tumors Early onset menses or late menopause Hereditary Factors Lynch Syndrome
Slide 5-

Lynch Syndrome (aka Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Inherited changes in genes that affect DNA mismatch repair (MMR) during DNA replication Autosomal Dominant Inheritance HAVING LYNCH SYNDROME DOES NOT MEAN YOU HAVE CANCER OR THAT YOU WILL DEFINITELY DEVELOP CANCER
Slide 6-

Lynch Syndrome & Risk of Endometrial Cancer
Slide 7-

Surveillance & Prevention Strategies Prompt reporting and evaluation of any abnormal uterine bleeding Consider screening with endometrial biopsy every 1-2 years starting at age 30-35 Hysterectomy as risk reducing option if completed childbearing Lynch Syndrome & Risk of Endometrial Cancer
Slide 8-

What if I Already Have Endometrial Cancer? Universal screening on all endometrial cancers Analysis of tumor for presence of 4 genes that are known to malfunction/mutated in Lynch syndrome MLH1, MSH2, MSH6, and PMS2 If all genes are expressed (normal)  Unlikely that a Lynch related pathogenic MMR deficiency is present If one (or more) of the genes are not expressed  Consider germline testing Unless defects in MLH1/PMS2  Hypermethylation tumor testing Microsatellite Instability (MSI) Changes in DNA sequence between normal tissue and tumor tissue Presence of MSI suggests malfunction in MMR genes Majority of microsatellite unstable tumors ARE NOT due to Lynch Syndrome
Slide 9-

ppt slide no 9 content not found
Slide 10-

Why Screening and Testing for Lynch Matters?
Slide 11-

ppt slide no 11 content not found
Slide 12-

Emma Barber, MD, MS Immunotherapy for Endometrial Cancer
Slide 13-

Immune System and Cancer
Slide 14-

Lynch Syndrome = Mismatch Repair Deficient
Slide 15-

Mismatch Repair Deficient Missing proteins that help the body repair DNA Cell accumulates many mistakes High mutation burden Microsatellite unstable Hypermutator phenotype Immune system more likely to recognize things that are unlike it
Slide 16-

Immune Check Point Inhibitors CTLA-4 Ipilimumab tremelimumab PD-1 Nivolumab Pembrolizumab PD-L1 Atezolizumab Avelumab Durvalumab
Slide 17-

Clinical Trial Results KEYNOTE-028 24 women with PD1 positive recurrent endometrial cancer 13% ORR 13% SD KEYNOTE-158 49 women with MMR deficient endometrial cancer ORR 57% Median PFS 25 months
Slide 18-

Immunotherapy for non-biomarker selected endometrial cancer Breakthrough FDA designation, now FDA approved Lenvatinib and Pembrolizumab 54 patients 40% ORR
Slide 19-

Ongoing Clinical Trials NRG GY-018 – Chemotherapy and pembrolizumab for women with stage III/IV (measureable disease) or recurrent endometrial cancer NRG GY-020 – Pembrolizumab and radiation therapy for high intermediate risk endometrial cancer Molecular subtyping of endometrial cancer – does immunotherapy replace chemotherapy?
Slide 20-

Thank you